Sayeda Yasmin-Karim, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation, Ionizing | 1 | 2018 | 251 | 0.580 |
Why?
|
Biocompatible Materials | 2 | 2021 | 1689 | 0.500 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2014 | 193 | 0.450 |
Why?
|
Sialoglycoproteins | 1 | 2014 | 316 | 0.440 |
Why?
|
Cancer Vaccines | 1 | 2018 | 1042 | 0.360 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2014 | 949 | 0.310 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9244 | 0.230 |
Why?
|
Radioimmunotherapy | 1 | 2021 | 93 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5444 | 0.180 |
Why?
|
Neoplasms | 4 | 2024 | 22350 | 0.170 |
Why?
|
Ultraviolet Rays | 1 | 2024 | 1100 | 0.160 |
Why?
|
Plant Leaves | 1 | 2020 | 153 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2023 | 4652 | 0.150 |
Why?
|
Graphite | 1 | 2018 | 77 | 0.150 |
Why?
|
Tumor Burden | 2 | 2021 | 1902 | 0.150 |
Why?
|
Vitamin D | 4 | 2012 | 3270 | 0.140 |
Why?
|
Fiducial Markers | 1 | 2018 | 134 | 0.140 |
Why?
|
Prostatic Neoplasms | 4 | 2014 | 11094 | 0.140 |
Why?
|
Oxides | 1 | 2018 | 402 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 877 | 0.130 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2016 | 106 | 0.130 |
Why?
|
Plant Extracts | 1 | 2020 | 496 | 0.130 |
Why?
|
Metal Nanoparticles | 1 | 2020 | 400 | 0.130 |
Why?
|
Nanoparticles | 2 | 2016 | 1966 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 348 | 0.120 |
Why?
|
Radiotherapy | 2 | 2024 | 1497 | 0.120 |
Why?
|
Nanostructures | 1 | 2018 | 549 | 0.110 |
Why?
|
Titanium | 1 | 2016 | 494 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1331 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1105 | 0.100 |
Why?
|
Receptors, Calcitriol | 2 | 2011 | 361 | 0.100 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3942 | 0.100 |
Why?
|
Photosensitizing Agents | 1 | 2016 | 627 | 0.100 |
Why?
|
Oxygen | 1 | 2023 | 4252 | 0.090 |
Why?
|
Receptor Cross-Talk | 1 | 2011 | 118 | 0.090 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 996 | 0.090 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3828 | 0.090 |
Why?
|
Mice | 7 | 2021 | 81898 | 0.090 |
Why?
|
Cell Adhesion | 2 | 2014 | 3093 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2060 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3605 | 0.090 |
Why?
|
Cell Line, Tumor | 5 | 2020 | 17089 | 0.080 |
Why?
|
Radiosurgery | 1 | 2018 | 1330 | 0.080 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 566 | 0.080 |
Why?
|
Endothelium | 1 | 2011 | 768 | 0.070 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4892 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2823 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3610 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8540 | 0.070 |
Why?
|
Animals | 7 | 2021 | 168939 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13489 | 0.060 |
Why?
|
Cell Movement | 1 | 2014 | 5204 | 0.050 |
Why?
|
Down-Regulation | 1 | 2010 | 2931 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4747 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2801 | 0.050 |
Why?
|
NF-kappa B | 1 | 2010 | 2493 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11062 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2011 | 3440 | 0.040 |
Why?
|
Erythrocyte Indices | 1 | 2020 | 143 | 0.040 |
Why?
|
Carcinoembryonic Antigen | 1 | 2020 | 338 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18329 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2024 | 2916 | 0.040 |
Why?
|
Immunity | 1 | 2023 | 1002 | 0.030 |
Why?
|
MicroRNAs | 1 | 2012 | 3789 | 0.030 |
Why?
|
Gold | 1 | 2020 | 482 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2020 | 1529 | 0.030 |
Why?
|
Male | 7 | 2021 | 364154 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2024 | 6066 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2018 | 65286 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2056 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9613 | 0.030 |
Why?
|
Hemoglobins | 1 | 2020 | 1531 | 0.030 |
Why?
|
Alleles | 1 | 2024 | 6896 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2198 | 0.030 |
Why?
|
Methylnitrosourea | 1 | 2011 | 30 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3043 | 0.020 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2011 | 67 | 0.020 |
Why?
|
Humans | 11 | 2024 | 766812 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2024 | 2355 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1251 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3435 | 0.020 |
Why?
|
Cell Aggregation | 1 | 2011 | 238 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2012 | 515 | 0.020 |
Why?
|
Signal Transduction | 2 | 2011 | 23618 | 0.020 |
Why?
|
Anemia | 1 | 2020 | 1514 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4427 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13644 | 0.020 |
Why?
|
Rheology | 1 | 2011 | 347 | 0.020 |
Why?
|
Brachytherapy | 1 | 2016 | 1221 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2011 | 457 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2010 | 826 | 0.020 |
Why?
|
E-Selectin | 1 | 2011 | 576 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5749 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1757 | 0.020 |
Why?
|
Microvessels | 1 | 2011 | 586 | 0.020 |
Why?
|
Cadherins | 1 | 2011 | 903 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8507 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15564 | 0.020 |
Why?
|
Melanoma | 1 | 2024 | 5702 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3618 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2016 | 5306 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30214 | 0.010 |
Why?
|
Cell Cycle | 1 | 2012 | 2925 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8623 | 0.010 |
Why?
|
Female | 2 | 2020 | 396532 | 0.010 |
Why?
|
DNA Repair | 1 | 2011 | 2050 | 0.010 |
Why?
|
DNA Damage | 1 | 2011 | 2469 | 0.010 |
Why?
|
Lung | 1 | 2020 | 10068 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8310 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2011 | 3139 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9326 | 0.010 |
Why?
|
Antigens, CD | 1 | 2011 | 4033 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2012 | 9546 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7612 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22351 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2011 | 3582 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3600 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10451 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2011 | 12795 | 0.010 |
Why?
|